<DOC>
	<DOCNO>NCT02176005</DOCNO>
	<brief_summary>The purpose study determine whether DAV132 safe effective capture fecal residue moxifloxacin healthy volunteer .</brief_summary>
	<brief_title>Safety Efficacy Study DAV132 Healthy Volunteers</brief_title>
	<detailed_description>The propose study , DAV132-CL-1002 , evaluate performance DAV132 healthy volunteer : - To capture residual concentration antibiotic colon without interfere systemic pharmacokinetics parameter . - To explore influence DAV132 prevent modification gut flora due antibiotic . In addition , security acceptability DAV132 use 7 day evaluate . The propose study prospective , randomize , control , four parallel group , repeat dos , open-label study blind analytical microbiological evaluation .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy volunteer Normal digestive transit , usually one daily stool . Females participate study : must either nonchild bear potential ( surgically sterilize least 3 month prior inclusion , postmenopausal negative pregnancy test breastfeeding screening , use abstinence double contraception method treatment period additional period 2 week end investigational treatment . Having give sign write study inform consent prior undertake studyrelated procedure . Covered French Health Insurance system . Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , haematological , neurological , bone joint , muscular , psychiatric , systemic , ocular , gynaecologic ( female ) , infectious disease , sign acute illness . Contraindications fluoroquinolones , risk factor adverse event associate fluoroquinolones . Subjects family history , actual glucose6phosphate dehydrogenase deficiency exclude . Subjects rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption exclude . Contraindications DAV132 , risk gastrointestinal obstruction , perforation haemorrhage , recent digestive tract surgery . Fecal colonisation Clostridium difficile . Recent history hospitalisation ( within 3 month prior inclusion ) . Any antibiotic administration within 3 month inclusion . Any vaccination within last 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>